In today’s briefing:
- HK Fintech Firm Banks $40m in Series A Money
- Agritech Startup Raises $1.8m Pre-Seed, Largest in Bangladesh
- Ex-Gojek VP’s Mobile Café Network Jago Nets US$2.2M Pre-Series A
- KYAN Therapeutics Bags US$5M to Bridge the Cancer Care Gap Using Tech
HK Fintech Firm Banks $40m in Series A Money
- Hong Kong-based Reap, a B2B fintech firm, has raised US$40 million in a series A funding round
- Founded in 2018 by Daren Guo and Kevin Kang, Reap’s platform helps users access payables management as well as international payments and collections.
- Through its data, the firm is able to lower costs for operating companies
Agritech Startup Raises $1.8m Pre-Seed, Largest in Bangladesh
- Agroshift, a Bangladesh-based agritech startup, raised US$1.8 million in a pre-seed round
Agroshift is an agricultural supply chain platform that helps farmers sell produce through demand aggregation, sourcing, and delivery.
Agroshift sets up digital ordering systems in factories, which workers order produce from. The firm aggregates these orders to farmers, then drops off the items at partnered factories.
Ex-Gojek VP’s Mobile Café Network Jago Nets US$2.2M Pre-Series A
- Jago offers a hyperlocal approach to retail by serving neighbourhoods within a 1-2km radius to prepare and deliver fresh beverages within minutes quickly
- Jago, an Indonesia-based mobile café network, today announced the completion of a US$2.2 million pre-Series A round of financing
- The funds will be directed towards expanding to over 200 mobile cafés, covering 20 hyperlocal areas in Jakarta. The company will also strengthen its core team in operations and technology.
KYAN Therapeutics Bags US$5M to Bridge the Cancer Care Gap Using Tech
- From drug development to personalised medicine, KYAN Therapeutics offers a solution to identify the optimal outcome for millions of possible drug-dose combinations
- Singapore-based KYAN Therapeutics, a biotech company with novel personalised medicine and drug-dose combination optimisation technology, has closed a US$5 million oversubscribed pre-Series A funding round.
- KYAN will use the funds to advance clinical development, expand lab infrastructure and treat more patients globally.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
